Radioterapia de salvamento para pacientes con cáncer de próstata: experiencia en el Instituto Nacional de Cancerología

Información del artículo

Resumen

Objetivo

describir la experiencia con radioterapia de salvamento en pacientes que presentaron recaída bioquímica, posterior a una prostatectomía radical, en el Instituto Nacional de Cancerología (INC).

Métodos

estudio observacional retrospectivo tipo serie de casos. Se recolectaron los casos atendidos entre 2003 y 2007. Se describió la información mediante estadística descriptiva, empleando frecuencias relativas, así como medidas de tendencia central y de dispersión. Se describió la supervivencia libre de enfermedad.

Resultados

un total de 40 pacientes que recibieron radioterapia de salvamento por recaída bioquímica fueron incluidos. La recaída posprostatectomía se presentó antes de dos años en el 65% de los pacientes. La mediana de PSA prerradioterapia en el presente estudio fue de 0,9ng/ml. El 87,5% de los pacientes fueron tratados con radioterapia conformacional 3D. El 97,5% de los pacientes recibieron una dosis total de 66 Gy. La supervivencia libre de enfermedad según la clasificación de riesgo de la enfermedad fue de 2,29 años, con una mediana de seguimiento de 28,5 meses. Dos pacientes presentaron recaída bioquímica posterior a la radioterapia de salvamento.

Conclusiones

la radioterapia de salvamento se muestra como una intervención apropiada en pacientes con cáncer de próstata que presentaron recaída bioquímica después de prostatectomía radical; el 94% de los pacientes tratados con radioterapia de rescate en el INC entre 2003 y 2007 están libres de recaída.

Palabras clave:

Neoplasias de la próstata

radioterapia

prostatectomía

antígeno prostático específico

Abstract

Objective

To describe a National Cancer Institute (NCI) study on rescue radiotherapy carried out among patients who had biochemical relapse following radical prostatectomy.

Methods

A retrospective, observational study was performed on cases treated from 2003 to 2007; descriptive statistics, using relative frequency as well as measures of central tendency and dispersion, were used to analyze information. Disease free survival was described.

Results

A total of 40 patients who underwent rescue radiotherapy for biochemical relapse were included in the study. Post-prostatectomy relapse occurred within 2 years in 65% of patients. Median pre-radiotherapy PSA was 0.9ng/ml. 3D conformational radiotherapy was used to treat 87.5% of cases; 97.5% of patients received a total dose of 66 Gy. In accordance with disease risk classification, disease free survival was 2.29 years, with 28.5 months median follow-up. Two patients had biochemical relapse following rescue radiotherapy.

Conclusions

Rescue radiotherapy has been shown to be an appropriate intervention for prostate cancer patients with biochemical relapse following radical prostatectomy; 94% of patients treated with rescue radiotherapy at the NCI from 2003 to 2007 are relapse free.

Key words:

Prostatic neoplasms

brachytherapy

prostatectomy

prostate-specific antigen

El Texto completo está disponible en PDF

Referencias

[1.]

D.F. Penson, J.M. Chan.

Pros tate cancer.

J Urol, 177 (2007), pp. 2020-2029

http://dx.doi.org/10.1016/j.juro.2007.01.121 | Medline

[2.]

J.D. Forman, K. Meetze, E. Pontes, et al.

Therapeutic irradiation for patients with an elevated postprostatectomy prostate specific antigen level.

J Urol, 158 (1997), pp. 1436-1439

Medline

[3.]

L.E. Lowes, M. Lock, G. Rodríguez, et al.

Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy.

Clin Transl Oncol, 14 (2012), pp. 150-156

http://dx.doi.org/10.1007/s12094-012-0775-5 | Medline

[4.]

M. Han, A.W. Partin, C.R. Pound, et al.

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15- year Johns Hopkins experience.

Urol Clin North Am, 28 (2001), pp. 555-565

Medline

[5.]

J.F. Ward, J.W. Moul.

Rising prostate-specific antigen after primary prostate cancer therapy.

Nat Clin Pract Urol, 2 (2005), pp. 174-182

http://dx.doi.org/10.1038/ncpuro0145 | Medline

[6.]

C.R. Pound, A.W. Partin, M.A. Eisenberger, et al.

Natural history of progression after PSA elevation following radical prostatectomy.

JAMA, 281 (1999), pp. 1591-1597

Medline

[7.]

M. Sia, T. Pickles, G. Morton, et al.

Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting.

Can Urol Assoc J, 2 (2008), pp. 500-507

Medline

[8.]

A.V. D’Amico, J.W. Moul, P.R. Carroll, et al.

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

J Natl Cancer Inst, 95 (2003), pp. 1376-1383

Medline

[9.]

S.G. Roberts, M.L. Blute, E.J. Bergstralh, et al.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Mayo Clin Proc, 76 (2001), pp. 576-581

http://dx.doi.org/10.4065/76.6.576 | Medline

[10.]

B. Shekarriz, J. Upadhyay, D.P. Wood Jr., et al.

Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage.

Urology, 54 (1999), pp. 1044-1048

Medline

[11.]

M. Bolla, P.H. van, L. Collette, et al.

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Lancet, 366 (2005), pp. 572-578

http://dx.doi.org/10.1016/S0140-6736(05)67101-2 | Medline

[12.]

I.M. Thompson Jr., C.M. Tangen, J. Paradelo, et al.

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

JAMA, 296 (2006), pp. 2329-2335

http://dx.doi.org/10.1001/jama.296.19.2329 | Medline

[13.]

T. Wiegel, S. Störkel, D. Bottke, et al.

Prostate cancer: Phase III study of adjuvant radiotherapy versus wait and see: Impact of pathologic review on analysis.

JCO, 27 (2009), pp. 2924-2930

[14.]

R. Choo, J. Kawakami, R. Siemens, et al.

Two different perspectives in the management of pT3 and/or marginpositive prostate cancer after radical prostatectomy.

BJU Int, 98 (2006), pp. 773-776

http://dx.doi.org/10.1111/j.1464-410X.2006.06423.x | Medline

[15.]

L. Boccon.

pT3 prostate cancer: the case for salvage (as opposed to adjuvant) radiation therapy.

Eur Urol Supp, 6 (2007), pp. 511-572

[16.]

C. Catton, M. Gospodarowicz, P. Warde, et al.

Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.

Radiother Oncol, 59 (2001), pp. 51-60

Medline

[17.]

D. Neuhof, T. Hentschel, M. Bischof, et al.

Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.

Int J Radiat Oncol Biol Phys, 67 (2007), pp. 1411-1417

http://dx.doi.org/10.1016/j.ijrobp.2006.11.024 | Medline

[18.]

A.J. Stephenson, S.F. Shariat, M.J. Zelefsky, et al.

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

JAMA, 291 (2004), pp. 1325-1332

http://dx.doi.org/10.1001/jama.291.11.1325 | Medline

[19.]

A.J. Stephenson, P.T. Scardino, M.W. Kattan, et al.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

J Clin Oncol, 25 (2007), pp. 2035-2041

http://dx.doi.org/10.1200/JCO.2006.08.9607 | Medline

[20.]

B.J. Trock, M. Han, S.J. Freedland, et al.

Prostate cancerspecific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

JAMA, 299 (2008), pp. 2760-2769

http://dx.doi.org/10.1001/jama.299.23.2760 | Medline

[21.]

J. Michalski, C. Lawton, I. El Naqa, et al.

Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Int J Radiat Oncol Biol Phys, 76 (2010), pp. 361-368

http://dx.doi.org/10.1016/j.ijrobp.2009.02.006 | Medline

[22.]

D.M. Moreira, L.L. Banez, J.C. Presti Jr., et al.

Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database.

BJU Int, 105 (2010), pp. 28-33

http://dx.doi.org/10.1111/j.1464-410X.2009.08684.x | Medline

[23.]

R. Umezawa, H. Ariga, Y. Ogawa, et al.

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0ng/ml.

Radiat Oncol, 6 (2011), pp. 150

http://dx.doi.org/10.1186/1748-717X-6-150 | Medline

[24.]

A. Siegmann, D. Bottke, J. Faehndrich, et al.

Salvage radiotherapy after prostatectomy - What is the best time to treat?.

Radiother Oncol, 103 (2012), pp. 239-243

http://dx.doi.org/10.1016/j.radonc.2011.10.024 | Medline

[25.]

T. Martin, F. Wenz, D. Bohmer, et al.

Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy.

Urologe A, 49 (2010), pp. 216-220

http://dx.doi.org/10.1007/s00120-010-2242-7 | Medline

[26.]

F. Wenz, T. Martin, D. Bohmer, et al.

The German S3 guideline prostate cancer: aspects for the radiation oncologist.

Strahlenther Onkol, 186 (2010), pp. 531-534

http://dx.doi.org/10.1007/s00066-010-2193-3 | Medline

[27.]

T. Budiharto, C. Perneel, K. Haustermans, et al.

A multiinstitutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy.

Radiother Oncol, 97 (2010), pp. 474-479

http://dx.doi.org/10.1016/j.radonc.2010.07.008 | Medline

[28.]

F. Pinto, T. Prayer-Galetti, M. Gardiman, et al.

Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer.

Urol Int, 76 (2006), pp. 202-208

http://dx.doi.org/10.1159/000091619 | Medline

[29.]

F.K. Chun, M. Graefen, M. Zacharias, et al.

Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer.

World J Urol, 24 (2006), pp. 273-280

http://dx.doi.org/10.1007/s00345-006-0058-2 | Medline

[30.]

P. Swindle, J.A. Eastham, M. Ohori, et al.

Do margins matter?.

The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol, 174 (2005), pp. 903-907

[31.]

L. Salomon, A.G. Anastasiadis, P. Antiphon, et al.

Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer.

Urol Int, 70 (2003), pp. 291-296

http://dx.doi.org/70138 | Medline

[32.]

K.A. Roehl, M. Han, C.G. Ramos, et al.

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.

J Urol, 172 (2004), pp. 910-914

http://dx.doi.org/10.1097/01.ju.0000134888.22332.bb | Medline

[33.]

E.J. Trabulsi, R.K. Valicenti, A.L. Hanlon, et al.

A multiinstitutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.

Urology, 72 (2008), pp. 1298-1302

http://dx.doi.org/10.1016/j.urology.2008.05.057 | Medline

[34.]

T. Wiegel, G. Lohm, D. Bottke, et al.

Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.

Int J Radiat Oncol Biol Phys, 73 (2009), pp. 1009-1016

http://dx.doi.org/10.1016/j.ijrobp.2008.06.1922 | Medline

[35.]

J.F. Ward, H. Zincke, E.J. Bergstralh, et al.

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.

J Urol, 172 (2004), pp. 2244-2248

Medline

[36.]

J.J. Coen, A.L. Zietman, H. Thakral, et al.

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

J Clin Oncol, 20 (2002), pp. 3199-3205

http://dx.doi.org/10.1200/JCO.2002.01.086 | Medline